Outcomes based on FISH risk among patients not eligible for ASCT
| Reference (trial) . | FISH . | Regimen . | HR-FISH/ SR-FISH (N) . | 3-y PFS, % . | 3-y OS, % . | ||
|---|---|---|---|---|---|---|---|
| HR-FISH . | SR-FISH . | HR-FISH . | SR-FISH . | ||||
| 20 (E9486) | Del(17p) | VBMCP | 37/308 | 17* | 30* | 32 | 68 |
| t(4;14) | VBMCP | 42/290 | 17* | 31* | 24 | 64 | |
| 18 (MRC IX non-intensive) | HR† | Melphalan/prednisone | 90/125 | N/A | 10 | 26 | 48 |
| CTDa | 96/129 | N/A | 20 | 58 | 78 | ||
| 15 (MRC IX maintenance) | HR† | Placebo maintenance (after all 4 inductions) | 98/129 | 18 | 30 | 69 | 72 |
| Thalidomide maintenance (after all 4 inductions) | 99/125 | 11 | 47 | 45 | 76 | ||
| 21 (FIRST trial) | HR‡ | Rd continuous | 43/205 | 3 | 45 | 41 | 77 |
| Rd 18-mo | 52/209 | 10 | 20 | 40 | 71 | ||
| MPT | 47/206 | 3 | 25 | 47 | 65 | ||
| 22 (Mayo Clinic) | HR§ | RD | 16/84 | 18 | 36 | 77 | 86 |
| 23 (E4A03) | HR§ | RD/Rd | 21/105 | 24 | 46 | 63 | 88 |
| 19 (VISTA) | HR‡ | VMP | 28/140 | N/A | N/A | 56 | 72 |
| 16,17 (GEM2005>65) | HR‡ | VMP→VT or VP | 44/187 | 18* | N/A | 51* | N/A |
| 24* | 33* | 55 | 77 | ||||
| HR‡ | VTP→VT or VP | 20* | N/A | 29* | N/A | ||
| Reference (trial) . | FISH . | Regimen . | HR-FISH/ SR-FISH (N) . | 3-y PFS, % . | 3-y OS, % . | ||
|---|---|---|---|---|---|---|---|
| HR-FISH . | SR-FISH . | HR-FISH . | SR-FISH . | ||||
| 20 (E9486) | Del(17p) | VBMCP | 37/308 | 17* | 30* | 32 | 68 |
| t(4;14) | VBMCP | 42/290 | 17* | 31* | 24 | 64 | |
| 18 (MRC IX non-intensive) | HR† | Melphalan/prednisone | 90/125 | N/A | 10 | 26 | 48 |
| CTDa | 96/129 | N/A | 20 | 58 | 78 | ||
| 15 (MRC IX maintenance) | HR† | Placebo maintenance (after all 4 inductions) | 98/129 | 18 | 30 | 69 | 72 |
| Thalidomide maintenance (after all 4 inductions) | 99/125 | 11 | 47 | 45 | 76 | ||
| 21 (FIRST trial) | HR‡ | Rd continuous | 43/205 | 3 | 45 | 41 | 77 |
| Rd 18-mo | 52/209 | 10 | 20 | 40 | 71 | ||
| MPT | 47/206 | 3 | 25 | 47 | 65 | ||
| 22 (Mayo Clinic) | HR§ | RD | 16/84 | 18 | 36 | 77 | 86 |
| 23 (E4A03) | HR§ | RD/Rd | 21/105 | 24 | 46 | 63 | 88 |
| 19 (VISTA) | HR‡ | VMP | 28/140 | N/A | N/A | 56 | 72 |
| 16,17 (GEM2005>65) | HR‡ | VMP→VT or VP | 44/187 | 18* | N/A | 51* | N/A |
| 24* | 33* | 55 | 77 | ||||
| HR‡ | VTP→VT or VP | 20* | N/A | 29* | N/A | ||
OS and PFS are estimated from Kaplan-Meier survival curves when necessary in an effort to normalize results to 3-year outcomes.
CTDa, attenuated cyclophosphamide, thalidomide, and dexamethasone regimen; MPT, melphalan, prednisone, and thaldiomide; N/A, not applicable; RD, lenalisomide plus dexamethasone; VBMCP, vincristine-carmustine (BCNU)-melphalan-cyclophosphamide-prednisone; VMP, bortezomib, melphalan, and prednisone; VP, bortezomib and prednisone; VT, bortezomib and thalidomide; VTP, bortezomib, thalidomide, and prednisone.
Median PFS, in months.
HR: Any of the following: gain(1q), t(4;14), t(14;20), t(14;16), and del(17p13).
HR: Any of the following: t(4;14), t(14;16), or del(17p13).
HR: Any of the following: hypodiploidy, monoallelic loss of chromosome 13 or its long-arm by metaphase cytogenetics only, deletion 17p13, t(4;14), or t(14;16), or plasma cell labeling index ≥3%.